Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Allogeneic Cell Cancer Immunotherapies"
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (20 October 2021) | Viewed by 23186
Special Issue Editor
Interests: low-cost IVF; pluipotent stem cells; translation of cell therapies; immune stem cell therapies for cancer and infection
Special Issue Information
Allogeneic immuno-cell therapies are beginning to replace autologous chimeric antigen receptor technologies (CAR-T). The major problem is the recognition of allogeneic cells by the recipient immune system that risks donor cell rejection and graft versus host disease. The approaches that are being developed include the use of compatible CAR-T cells derived from HLA-matched donors, derivation of haplotype-induced pluripotent stem cells (iPSCs), gene knock-out of the T cell receptor (TCR) or the major histocompatibility loci (HLAs), the use of natural killer (NK) cells or NKT cells, or combinations of several of these approaches. Given the success of CAR-T for B cell blood cancers, considerable effort is underway to enable single CAR-T products to treat large numbers of patients in a cost-effective way. The ability of gene stem cells to insert CARs into safe harbor sites in the genome and to knock out checkpoint inhibitor genes that prevent tumor destruction is being trialed in animal models and in early-stage clinical trials. These studies are targeted at multiple blood and solid cancers, and also at cells infected with pathological viruses such as HIV and COVID-19. Early progress is encouraging, but the outcome of human clinical trials remains essential to evaluate the safety and efficacy of these new allogeneic cell therapy approaches.
Prof. Alan Trounson
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- allogeneic cell therapy
- pluripotent stem cells
- gene editing